CB1

CB1 is the main cannabinoid receptor in the brain but is also found in other tissues. CB1 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently reduces cAMP upon activation. This in turn regulates many second messenger pathways. 

Depression

Both plant cannabinoids and the endocannabinoid system have been implicated as risk factors in the development of depression as well as therapeutic targets to treat depression.

Huntington's

Huntington's disease is a genetic neurodegenerative disorder, marked by preferential degeneration of neurons in the basal ganglia (caudate and putamen) and accompanied by motor deficits, cognitive impairment and psychiatric symptoms.

COPD

COPD is a chronic lung disease. To date, no cure exists for COPD and therefore most treatments focus on reducing symptoms and suppressing discomfort.

OCD

OCD is an anxiety disorder characterised by the obsessive urge for repetitive behaviour.

Psoriasis

Psoriasis is an auto-immune disease characterized by itchy skin lesions. Psoriasis arises when the immune system mistakenly identifies skin cells as foreign matter and causes over-production of new skin cells.

Epilepsy

cannabinoids have excellent therapeutic potential for the treatment of epilepsy. In the brain, the endocannabinoid system tends to keep neuronal activity wihtin acceptable boundaries.

Pain

pain is a very good target for therapeutic cannabinoids.

CBG

CBG is a non-psychoactive cannabinoid with therapeutic potential in cancer, Huntington's Disease, eating disorders, gastrointestinal inflammation, glaucoma and Psoriasis.

TRPV3

TRPV3 is one of the non-GPCR-coupled cannabinoid receptors. TRPs are typically involved in pain sensation.